Fesoterodine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (5)Enzymes (2)Transporters (1)

Targets (5)Enzymes (2)Transporters (1)Biointeractions (8)

Identification

Name

Fesoterodine

Accession Number

DB06702

Type

Small Molecule

Groups

Approved

Description

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

FESO

Fesoterodine

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Fesoterodine fumarate	EOS72165S7	286930-03-8	MWHXMIASLKXGBU-RNCYCKTQSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2012-04-19	Not applicable	Canada
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	4 mg/1	Oral	Physicians Total Care, Inc.	2010-08-23	Not applicable	US
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	8 mg/1	Oral	Cardinal Health	2008-10-31	Not applicable	US
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	4 mg/1	Oral	Avera Mc Kennan Hospital	2015-04-01	Not applicable	US
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	8 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2008-10-31	Not applicable	US
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	8 mg/1	Oral	Physicians Total Care, Inc.	2010-09-15	Not applicable	US
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	8 mg/1	Oral	U.S. Pharmaceuticals	2008-10-31	Not applicable	US
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	8 mg/1	Oral	Avera Mc Kennan Hospital	2015-06-10	Not applicable	US
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2012-04-19	Not applicable	Canada
Toviaz	Tablet, film coated, extended release	4 mg/1	Oral	Cardinal Health	2008-10-31	Not applicable	US
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, extended release	4 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	4 mg/1	Oral	U.S. Pharmaceuticals	2008-10-31	Not applicable	US
Toviaz	Tablet, extended release	8 mg	Oral	Pfizer	2007-04-20	Not applicable	EU
Toviaz	Tablet, film coated, extended release	4 mg/1	Oral	Pfizer Laboratories Div Pfizer Inc.	2008-10-31	Not applicable	US

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

621G617227

CAS number

286930-02-7

Weight

Average: 411.5769
Monoisotopic: 411.277344055

Chemical Formula

C₂₆H₃₇NO₃

InChI Key

DCCSDBARQIPTGU-HSZRJFAPSA-N

InChI

InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1

IUPAC Name

2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate

SMILES

CC(C)N(CC[[email protected]](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C

Pharmacology

Indication

For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).

Structured Indications

Over Active Bladder

Pharmacodynamics

Fesoterodine is a prodrug. In-vivo it is broken down into its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), by plasma esterases. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. Therefore, acting as a competitive muscarinic receptor antagonist, fesoterodine ultimately acts to decrease the detrusor pressure by its muscarinic antagonism, thereby decreasing bladder contraction and consequently, the urge to urinate.

Mechanism of action

Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Muscarinic acetylcholine receptor M3	Protein	yes	antagonist	Human	P20309	details
Muscarinic acetylcholine receptor M4	Protein	unknown	antagonist	Human	P08173	details
Muscarinic acetylcholine receptor M1	Protein	unknown	antagonist	Human	P11229	details
Muscarinic acetylcholine receptor M2	Protein	unknown	antagonist	Human	P08172	details
Muscarinic acetylcholine receptor M5	Protein	unknown	antagonist	Human	P08912	details

Absorption

Tmax (5-HMT): 5 hours post-adminitration of fesoterodine. AUC (0,∞)= 49.5 ng·h/ ml
Bioavailability, 5-HMT = 52%

Volume of distribution

IV, 5-HMT: 169 L

Protein binding

5-HMT: 50% to albumin and alpha1-acid glycoprotein

Metabolism

Metabolized by ubiquitous, nonspecific esterases to transform fesoterodine into 5-HMT Extensive metabolism via CYP2D6 and CYP3A4 into inactive metabolites

Route of elimination

Renal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite Fecal: 7% Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4

Half life

7-8 hours for the active metabolite 5-hydroxymethyl tolterodine

Clearance

5-HMT, healthy subjects: 14.4 L/h 5-HMT is also secreted into the nephron.

Toxicity

Rat, Oral, LD50: ~ 681 mg/kg Mouse, Oral, LD50: ~ 316 mg/kg Rat, Intravenous, NOAEL: 10 mg/kg Mouse, Intravenous, NOAEL: 10 mg/kg

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Cytochrome P450 2D6	CYP2D6*3	Not Available	C allele	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*4	Not Available	C allele	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*5	Not Available	Whole-gene deletion	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*6	Not Available	1707delT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*7	Not Available	2935A>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*8	Not Available	1758G>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*11	Not Available	883G>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*12	Not Available	124G>A	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*13	Not Available	CYP2D7/2D6 hybrid gene structure	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*14A	Not Available	1758G>A	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*15	Not Available	137insT, 137_138insT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*19	Not Available	2539_2542delAACT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*20	Not Available	1973_1974insG	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*21	Not Available	2573insC	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*31	Not Available	-1770G>A / -1584C>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*36	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*38	Not Available	2587_2590delGACT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*40	Not Available	1863_1864ins(TTT CGC CCC)2	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*42	Not Available	3259_3260insGT	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*44	Not Available	2950G>C	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*47	Not Available	100C>T / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*51	Not Available	-1584C>G / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*56	Not Available	3201C>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*57	Not Available	100C>T / 310G>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*62	Not Available	4044C>T	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*68A	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*68B	Not Available	Similar but not identical switch region compared to CYP2D668A. Found in tandem arrangement with CYP2D64.	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*69	Not Available	2988G>A / -1426C>T … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*92	Not Available	1995delC	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*100	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details
Cytochrome P450 2D6	CYP2D6*101	Not Available	-1426C>T / -1235A>G … show all	Effect Inferred	Poor drug metabolizer.	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.	Experimental
Abiraterone	The serum concentration of Fesoterodine can be increased when it is combined with Abiraterone.	Approved
Acebutolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.	Approved
Acetaminophen	The serum concentration of Fesoterodine can be increased when it is combined with Acetaminophen.	Approved
Aclidinium	Aclidinium may increase the anticholinergic activities of Fesoterodine.	Approved
Afatinib	The serum concentration of Fesoterodine can be increased when it is combined with Afatinib.	Approved
Ajmaline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ajmaline.	Approved
Albendazole	The serum concentration of Fesoterodine can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Fesoterodine can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Fesoterodine can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Fesoterodine can be increased when it is combined with Alfentanil.	Approved, Illicit
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Alphacetylmethadol.	Experimental, Illicit
Amantadine	The serum concentration of Fesoterodine can be increased when it is combined with Amantadine.	Approved
Ambenonium	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ambenonium.	Approved
Aminohippuric acid	The serum concentration of Fesoterodine can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.	Approved
Amlodipine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amlodipine.	Approved
Amodiaquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amodiaquine.	Approved
Amphetamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amphetamine.	Approved, Illicit
Amprenavir	The serum concentration of Fesoterodine can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Fesoterodine can be increased when it is combined with Amsacrine.	Approved
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fesoterodine.	Approved
Antipyrine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.	Approved
Aprepitant	The serum concentration of Fesoterodine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.	Approved, Investigational
Artemether	The metabolism of Fesoterodine can be decreased when combined with Artemether.	Approved
Asenapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Asenapine.	Approved
Astemizole	The serum concentration of Fesoterodine can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Fesoterodine can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atomoxetine.	Approved
Atorvastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.	Approved
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Fesoterodine.	Approved, Vet Approved
Azelastine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Azelastine.	Approved
Azithromycin	The serum concentration of Fesoterodine can be increased when it is combined with Azithromycin.	Approved
Benactyzine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Benactyzine.	Withdrawn
Bendroflumethiazide	The serum concentration of Bendroflumethiazide can be increased when it is combined with Fesoterodine.	Approved
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Fesoterodine.	Approved
Benzocaine	The serum concentration of Fesoterodine can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Fesoterodine can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betaxolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.	Approved
Bexarotene	The serum concentration of Fesoterodine can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezitramide	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Bezitramide.	Experimental, Illicit, Withdrawn
Bicalutamide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bicalutamide.	Approved
Biperiden	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Biperiden.	Approved
Boceprevir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.	Withdrawn
Bortezomib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Fesoterodine can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Fesoterodine can be increased when it is combined with Bosutinib.	Approved
Botulinum Toxin Type A	Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.	Approved, Investigational
Botulinum Toxin Type B	Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.	Approved
Bromocriptine	The serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.	Approved, Investigational
Brompheniramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.	Approved
Buprenorphine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Bupropion.	Approved
Buspirone	The serum concentration of Fesoterodine can be increased when it is combined with Buspirone.	Approved, Investigational
Butorphanol	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.	Approved, Illicit, Vet Approved
Cabazitaxel	The serum concentration of Fesoterodine can be increased when it is combined with Cabazitaxel.	Approved
Caffeine	The serum concentration of Fesoterodine can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Fesoterodine can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Fesoterodine can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Fesoterodine can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Fesoterodine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Carfentanil.	Illicit, Vet Approved
Carteolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Carteolol.	Approved
Carvedilol	The serum concentration of Fesoterodine can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Fesoterodine can be increased when it is combined with Caspofungin.	Approved
Celecoxib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.	Approved, Investigational
Ceritinib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ceritinib.	Approved
Cerivastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cerivastatin.	Withdrawn
Chloroquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.	Approved, Vet Approved
Chlorphenamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorphenamine.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Chlorphenoxamine.	Withdrawn
Chlorpromazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Fesoterodine can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Fesoterodine can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	The serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.	Approved
Cholecalciferol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cholecalciferol.	Approved, Nutraceutical
Cholesterol	The serum concentration of Fesoterodine can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Fesoterodine can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Fesoterodine can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.	Approved
Cimetropium	Fesoterodine may increase the anticholinergic activities of Cimetropium.	Experimental
Cinacalcet	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cinacalcet.	Approved
Ciprofloxacin	The serum concentration of Fesoterodine can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Cisapride	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cisapride.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.	Approved
Clarithromycin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clarithromycin.	Approved
Clemastine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clemastine.	Approved
Clobazam	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clobazam.	Approved, Illicit
Clofazimine	The serum concentration of Fesoterodine can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clomipramine.	Approved, Vet Approved
Clotrimazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clozapine.	Approved
Cobicistat	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cobicistat.	Approved
Cocaine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cocaine.	Approved, Illicit
Codeine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.	Approved, Illicit
Colchicine	The serum concentration of Fesoterodine can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Fesoterodine can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Fesoterodine can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The metabolism of Fesoterodine can be decreased when combined with Crizotinib.	Approved
Cyclopentolate	The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fesoterodine.	Approved
Cyclophosphamide	The serum concentration of Fesoterodine can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.	Approved, Investigational, Vet Approved
Dabrafenib	The serum concentration of Fesoterodine can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Fesoterodine can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Fesoterodine can be increased when it is combined with Dactinomycin.	Approved
Darifenacin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin.	Approved, Investigational
Darunavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darunavir.	Approved
Dasatinib	The serum concentration of Fesoterodine can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Fesoterodine can be decreased when it is combined with Daunorubicin.	Approved
Decamethonium	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Decamethonium.	Approved
Deferasirox	The serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.	Approved
Demecarium	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Demecarium.	Approved
Desipramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.	Approved
Desloratadine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Fesoterodine can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexetimide	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dexetimide.	Withdrawn
Dexfenfluramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexfenfluramine.	Approved, Illicit, Withdrawn
Dexmedetomidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmedetomidine.	Approved, Vet Approved
Dexmethylphenidate	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dexmethylphenidate.	Approved
Dextroamphetamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextroamphetamine.	Approved, Illicit
Dextromethorphan	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextromethorphan.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dezocine.	Approved
Diclofenac	The serum concentration of Fesoterodine can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.	Approved
Digoxin	The serum concentration of Fesoterodine can be decreased when it is combined with Digoxin.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The metabolism of Fesoterodine can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diltiazem.	Approved
Dimethyl sulfoxide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide.	Approved, Vet Approved
Diphenhydramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The serum concentration of Fesoterodine can be increased when it is combined with Dipyridamole.	Approved
Donepezil	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Donepezil.	Approved
Doxazosin	The serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.	Approved
Doxorubicin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Fesoterodine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	Fesoterodine may increase the tachycardic activities of Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dronedarone.	Approved
Duloxetine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.	Approved
Echothiophate	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate.	Approved
Edrophonium	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Edrophonium.	Approved
Efavirenz	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.	Approved, Investigational
Elbasvir	The serum concentration of Fesoterodine can be increased when it is combined with Elbasvir.	Approved
Eliglustat	The metabolism of Fesoterodine can be decreased when combined with Eliglustat.	Approved
Eluxadoline	Fesoterodine may increase the constipating activities of Eluxadoline.	Approved
Enalapril	The serum concentration of Fesoterodine can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Epinastine.	Approved, Investigational
Ergonovine	The serum concentration of Fesoterodine can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Fesoterodine can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The metabolism of Fesoterodine can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Fesoterodine can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estramustine	The serum concentration of Fesoterodine can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Fesoterodine can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Fesoterodine can be decreased when it is combined with Estrone.	Approved
Ethanol	Ethanol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.	Approved
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Fesoterodine.	Approved
Ethylmorphine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ethylmorphine.	Approved, Illicit
Etoposide	The serum concentration of Fesoterodine can be increased when it is combined with Etoposide.	Approved
Etoricoxib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Etoricoxib.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Fesoterodine can be decreased when it is combined with Etravirine.	Approved
Felodipine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.	Approved, Investigational
Fenfluramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fenfluramine.	Illicit, Withdrawn
Fentanyl	The serum concentration of Fesoterodine can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Fesoterodine can be increased when it is combined with Fidaxomicin.	Approved
Flecainide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Flecainide.	Approved, Withdrawn
Fluconazole	The metabolism of Fesoterodine can be decreased when combined with Fluconazole.	Approved
Fluoxetine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Fesoterodine can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.	Approved
Flurazepam	The serum concentration of Fesoterodine can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluvastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvastatin.	Approved
Fluvoxamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Fesoterodine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Fesoterodine can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Fesoterodine can be increased when combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Fesoterodine can be increased when it is combined with Fusidic Acid.	Approved
Galantamine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Fesoterodine.	Approved
Gefitinib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Fesoterodine can be increased when it is combined with Genistein.	Investigational
Ginkgo biloba	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Ginkgo biloba.	Approved, Nutraceutical
Glucagon recombinant	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.	Approved
Glyburide	The serum concentration of Fesoterodine can be increased when it is combined with Glyburide.	Approved
Glycopyrronium	Fesoterodine may increase the anticholinergic activities of Glycopyrronium.	Approved, Investigational, Vet Approved
Gramicidin D	The serum concentration of Fesoterodine can be increased when it is combined with Gramicidin D.	Approved
Granisetron	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Granisetron.	Approved, Investigational
Grepafloxacin	The serum concentration of Fesoterodine can be increased when it is combined with Grepafloxacin.	Withdrawn
Halofantrine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Halofantrine.	Approved
Haloperidol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.	Approved
Heroin	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Heroin.	Approved, Illicit
Hexamethonium	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hexamethonium.	Experimental
Histamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Histamine Phosphate.	Approved, Investigational
Huperzine A	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Huperzine A.	Investigational
Hydrochlorothiazide	The serum concentration of Hydrochlorothiazide can be increased when it is combined with Fesoterodine.	Approved, Vet Approved
Hydrocodone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.	Approved, Illicit
Hydrocortisone	The serum concentration of Fesoterodine can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Hydroflumethiazide	The serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydromorphone.	Approved, Illicit
Hydroxychloroquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine.	Approved
Hydroxyurea	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyurea.	Approved
Hydroxyzine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fesoterodine.	Approved
Idarubicin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Idarubicin.	Approved
Idelalisib	The serum concentration of Fesoterodine can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imatinib.	Approved
Imipramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.	Approved
Indapamide	The serum concentration of Indapamide can be increased when it is combined with Fesoterodine.	Approved
Indinavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Indinavir.	Approved
Indomethacin	The serum concentration of Fesoterodine can be increased when it is combined with Indomethacin.	Approved, Investigational
Ipratropium bromide	The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.	Approved
Irbesartan	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.	Approved, Investigational
Isavuconazonium	The metabolism of Fesoterodine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isoflurophate	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.	Approved, Withdrawn
Isoniazid	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Isoniazid.	Approved
Isradipine	The metabolism of Fesoterodine can be decreased when combined with Isradipine.	Approved
Itopride	The therapeutic efficacy of Itopride can be decreased when used in combination with Fesoterodine.	Investigational
Itraconazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Fesoterodine can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Fesoterodine can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Fesoterodine can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Ketobemidone.	Approved
Ketoconazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ketoconazole.	Approved, Investigational
Labetalol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.	Approved
Lansoprazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Fesoterodine can be increased when it is combined with Lapatinib.	Approved, Investigational
Lercanidipine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lercanidipine.	Approved, Investigational
Levofloxacin	The serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.	Approved
Levothyroxine	The serum concentration of Fesoterodine can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Fesoterodine can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Fesoterodine can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Fesoterodine can be increased when it is combined with Lisinopril.	Approved, Investigational
Lofentanil	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Lofentanil.	Illicit
Lomitapide	The serum concentration of Fesoterodine can be increased when it is combined with Lomitapide.	Approved
Lomustine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lomustine.	Approved
Loperamide	The serum concentration of Fesoterodine can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.	Approved
Loratadine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Loratadine.	Approved
Lorcaserin	The metabolism of Fesoterodine can be decreased when combined with Lorcaserin.	Approved
Losartan	The serum concentration of Fesoterodine can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Fesoterodine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Fesoterodine can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lumefantrine.	Approved
Malathion	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Malathion.	Approved, Investigational
Maprotiline	The serum concentration of Fesoterodine can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Fesoterodine can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.	Approved
Mefloquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Fesoterodine can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Memantine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Memantine.	Approved, Investigational
Meprobamate	The serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.	Approved, Illicit
Mepyramine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mepyramine.	Approved, Vet Approved
Methadone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methamphetamine.	Approved, Illicit
Methanesulfonyl Fluoride	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Methanesulfonyl Fluoride.	Investigational
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Fesoterodine.	Approved
Methazolamide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methazolamide.	Approved
Methimazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.	Approved
Methotrimeprazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methotrimeprazine.	Approved
Methyclothiazide	The serum concentration of Methyclothiazide can be increased when it is combined with Fesoterodine.	Approved
Methylnaltrexone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylnaltrexone.	Approved
Methylphenidate	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.	Approved, Investigational
Metixene	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Metixene.	Approved
Metoclopramide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoclopramide.	Approved, Investigational
Metolazone	The serum concentration of Metolazone can be increased when it is combined with Fesoterodine.	Approved
Metoprolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.	Approved, Investigational
Mianserin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mianserin.	Approved
Mibefradil	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mibefradil.	Withdrawn
Miconazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.	Approved, Illicit
Midodrine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Midodrine.	Approved
Mifepristone	The serum concentration of Fesoterodine can be increased when it is combined with Mifepristone.	Approved, Investigational
Minaprine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Minaprine.	Approved
Mirabegron	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.	Approved
Mirtazapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.	Approved
Mitomycin	The serum concentration of Fesoterodine can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Fesoterodine can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Fesoterodine can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Moclobemide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.	Approved
Modafinil	The serum concentration of Fesoterodine can be decreased when it is combined with Modafinil.	Approved, Investigational
Morphine	The serum concentration of Fesoterodine can be increased when it is combined with Morphine.	Approved, Investigational
Nabilone	Fesoterodine may increase the tachycardic activities of Nabilone.	Approved, Investigational
Nafcillin	The serum concentration of Fesoterodine can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Nalbuphine.	Approved
Naloxegol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Naloxegol.	Approved
Naltrexone	The serum concentration of Fesoterodine can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Fesoterodine can be increased when it is combined with Naringenin.	Experimental
Nefazodone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.	Approved
Neostigmine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Fesoterodine can be increased when it is combined with Netupitant.	Approved
Nevirapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nevirapine.	Approved
Niacin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Niacin.	Approved, Investigational, Nutraceutical
Nicardipine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.	Approved
Nicotinamide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicotinamide.	Approved
Nifedipine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nifedipine.	Approved
Nilotinib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.	Approved, Investigational
Nisoldipine	The serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Fesoterodine can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.	Approved
Norethisterone	The serum concentration of Fesoterodine can be decreased when it is combined with Norethisterone.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Normethadone.	Approved, Illicit
Nortriptyline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.	Approved
Olanzapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.	Approved, Investigational
Olaparib	The metabolism of Fesoterodine can be decreased when combined with Olaparib.	Approved
Omeprazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Opium.	Approved, Illicit
Orphenadrine	The risk or severity of adverse effects can be increased when Orphenadrine is combined with Fesoterodine.	Approved
Osimertinib	The serum concentration of Fesoterodine can be increased when it is combined with Osimertinib.	Approved
Oxamniquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxamniquine.	Approved
Oxprenolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.	Approved
Oxybutynin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxybutynin.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymetholone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxymetholone.	Approved, Illicit
Oxymorphone	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fesoterodine.	Approved
P-Nitrophenol	The serum concentration of Fesoterodine can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Fesoterodine can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Fesoterodine can be increased when it is combined with Palmitic Acid.	Experimental
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.	Approved
Panobinostat	The serum concentration of Fesoterodine can be increased when it is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The serum concentration of Fesoterodine can be increased when it is combined with Pantoprazole.	Approved
Paroxetine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.	Approved, Investigational
Peginterferon alfa-2b	The serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The metabolism of Fesoterodine can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Fesoterodine.	Approved
Pergolide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pergolide.	Approved, Vet Approved, Withdrawn
Perhexiline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perhexiline.	Approved
Perindopril	The serum concentration of Fesoterodine can be increased when it is combined with Perindopril.	Approved
Perphenazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pethidine.	Approved
Phenobarbital	The metabolism of Fesoterodine can be increased when combined with Phenobarbital.	Approved
Phentermine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Phentermine.	Approved, Illicit
Phenytoin	The metabolism of Fesoterodine can be increased when combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Physostigmine.	Approved
Pimozide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.	Approved
Pindolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pindolol.	Approved
Pioglitazone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pioglitazone.	Approved, Investigational
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.	Approved
Pipotiazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pipotiazine.	Approved
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Piritramide.	Investigational
Platelet Activating Factor	The serum concentration of Fesoterodine can be decreased when it is combined with Platelet Activating Factor.	Experimental
Polythiazide	The serum concentration of Polythiazide can be increased when it is combined with Fesoterodine.	Approved
Ponatinib	The serum concentration of Fesoterodine can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Posaconazole.	Approved, Investigational, Vet Approved
Potassium Chloride	Fesoterodine may increase the ulcerogenic activities of Potassium Chloride.	Approved, Withdrawn
Pramlintide	Pramlintide may increase the anticholinergic activities of Fesoterodine.	Approved, Investigational
Pravastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.	Approved
Praziquantel	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.	Approved, Vet Approved
Prazosin	The serum concentration of Fesoterodine can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Fesoterodine can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primaquine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Primaquine.	Approved
Primidone	The metabolism of Fesoterodine can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Fesoterodine can be increased when it is combined with Probenecid.	Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Fesoterodine.	Approved
Progesterone	The serum concentration of Fesoterodine can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proguanil	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Proguanil.	Approved
Promazine	The metabolism of Fesoterodine can be decreased when combined with Promazine.	Approved, Vet Approved
Promethazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.	Approved
Propafenone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.	Approved
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Fesoterodine.	Approved
Propiverine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Propiverine.	Investigational
Propofol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.	Approved
Pyridostigmine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pyridostigmine.	Approved
Pyrimethamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine.	Approved, Vet Approved
Quercetin	The serum concentration of Fesoterodine can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.	Approved
Quinacrine	The serum concentration of Fesoterodine can be increased when it is combined with Quinacrine.	Approved
Quinethazone	The serum concentration of Quinethazone can be increased when it is combined with Fesoterodine.	Approved
Quinidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinidine.	Approved
Quinine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quinine.	Approved
Rabeprazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.	Approved, Investigational
Ramosetron	Fesoterodine may increase the constipating activities of Ramosetron.	Approved
Ranitidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranitidine.	Approved
Ranolazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Fesoterodine can be increased when it is combined with Regorafenib.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.	Approved
Reserpine	The serum concentration of Fesoterodine can be decreased when it is combined with Reserpine.	Approved
Rifabutin	The metabolism of Fesoterodine can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Fesoterodine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Fesoterodine can be increased when combined with Rifapentine.	Approved
Rilpivirine	The serum concentration of Fesoterodine can be increased when it is combined with Rilpivirine.	Approved
Risperidone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.	Approved, Investigational
Ritonavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.	Approved, Investigational
Rivastigmine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rivastigmine.	Approved, Investigational
Rolapitant	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rolapitant.	Approved
Ropinirole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ropinirole.	Approved, Investigational
Rosiglitazone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rosiglitazone.	Approved, Investigational
Rotigotine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rotigotine.	Approved
Rutin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rutin.	Experimental
Saquinavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine.	Approved
Scopolamine butylbromide	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Scopolamine butylbromide.	Approved, Vet Approved
Secretin	The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.	Approved, Investigational
Selegiline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Selegiline.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.	Approved
Sildenafil	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Fesoterodine can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Fesoterodine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin.	Approved
Sirolimus	The serum concentration of Fesoterodine can be decreased when it is combined with Sirolimus.	Approved, Investigational
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Fesoterodine.	Approved
Sorafenib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sorafenib.	Approved, Investigational
Sparteine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sparteine.	Experimental
Spironolactone	The serum concentration of Fesoterodine can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Fesoterodine can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Fesoterodine can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Fesoterodine can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Fesoterodine can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.	Approved, Investigational
Sulfanilamide	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide.	Approved
Sulfaphenazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfaphenazole.	Approved
Sulfinpyrazone	The serum concentration of Fesoterodine can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Fesoterodine can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The therapeutic efficacy of Sulpiride can be decreased when used in combination with Fesoterodine.	Approved
Sumatriptan	The serum concentration of Fesoterodine can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Fesoterodine can be increased when it is combined with Sunitinib.	Approved, Investigational
Tacrine	The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Fesoterodine can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tamoxifen.	Approved
Tapentadol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.	Approved
Taurocholic Acid	The serum concentration of Fesoterodine can be increased when it is combined with Taurocholic Acid.	Experimental
Tegaserod	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tegaserod.	Investigational, Withdrawn
Telaprevir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Telithromycin.	Approved
Telmisartan	The serum concentration of Fesoterodine can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.	Approved
Terazosin	The serum concentration of Fesoterodine can be increased when it is combined with Terazosin.	Approved
Terbinafine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terbinafine.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Fesoterodine can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Fesoterodine can be increased when it is combined with Testosterone.	Approved, Investigational
Thioridazine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.	Withdrawn
Thiothixene	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thiothixene.	Approved
Ticagrelor	The serum concentration of Fesoterodine can be increased when it is combined with Ticagrelor.	Approved
Ticlopidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ticlopidine.	Approved
Tiotropium	Fesoterodine may increase the anticholinergic activities of Tiotropium.	Approved
Tipranavir	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.	Approved, Investigational
Tocilizumab	The serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Fesoterodine.	Approved, Investigational
Tolvaptan	The serum concentration of Fesoterodine can be increased when it is combined with Tolvaptan.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Topiramate.	Approved
Tramadol	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.	Approved, Investigational
Tranylcypromine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.	Approved
Trazodone	The serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.	Approved, Investigational
Trichlormethiazide	The serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Fesoterodine can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Fesoterodine can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fesoterodine.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Fesoterodine.	Approved
Trimethoprim	The serum concentration of Fesoterodine can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Fesoterodine can be increased when it is combined with Trimipramine.	Approved
Tripelennamine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tripelennamine.	Approved, Vet Approved
Triprolidine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Triprolidine.	Approved
Tropicamide	The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine.	Approved
Trospium	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Trospium.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Fesoterodine.	Approved
Umeclidinium	Umeclidinium may increase the anticholinergic activities of Fesoterodine.	Approved
Vecuronium	The risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.	Approved
Vemurafenib	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vemurafenib.	Approved
Venlafaxine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Venlafaxine.	Approved
Verapamil	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.	Approved
Vinblastine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinblastine.	Approved
Vincristine	The serum concentration of Fesoterodine can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.	Approved, Investigational
Voriconazole	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Voriconazole.	Approved, Investigational
Yohimbine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Yohimbine.	Approved, Vet Approved
Zafirlukast	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Zafirlukast.	Approved, Investigational
Zimelidine	The serum concentration of Fesoterodine can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.	Approved

Food Interactions

Take with or without food.

References

Synthesis Reference

Claus Meese, "CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF." U.S. Patent US20090192224, issued July 30, 2009.

US20090192224

General References

Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. [PubMed:19835561 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15648
KEGG Drug	D07226
PubChem Compound	6918558
PubChem Substance	99443256
ChemSpider	5293755
ChEBI	135920
ChEMBL	CHEMBL1201764
PharmGKB	PA165958376
Drug Product Database	21178
RxList	http://www.rxlist.com/toviaz-drug.htm
Drugs.com	http://www.drugs.com/cdi/fesoterodine.html
Wikipedia	Fesoterodine

ATC Codes

G04BD11 — Fesoterodine

AHFS Codes

12:08.08

PDB Entries

Not Available

FDA label

Download (430 KB)

MSDS

Download (102 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	Over Active Bladder	1
1	Completed	Not Available	Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency	1
1	Completed	Not Available	Treatment of Overactive Bladder	2
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Basic Science	Urinary Bladder, Overactive	1
1	Completed	Treatment	Food / Therapeutic Equivalency	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence	1
1	Terminated	Treatment	Healthy Volunteers	1
2	Completed	Treatment	Neurogenic Detrusor Overactivity / Over Active Bladder	1
2	Completed	Treatment	Over Active Bladder	1
2	Completed	Treatment	Stress Urinary Incontinence (SUI)	1
2	Recruiting	Not Available	Mild Cognitive Impairment (MCI) / Over Active Bladder	1
2	Recruiting	Treatment	Autonomic Dysreflexia	1
2, 3	Terminated	Treatment	Nocturia	1
3	Active Not Recruiting	Treatment	Urge Urinary Incontinence	1
3	Completed	Treatment	Over Active Bladder	5
3	Completed	Treatment	Overactive Bladder Syndrome	1
3	Enrolling by Invitation	Treatment	Over Active Bladder	1
3	Recruiting	Treatment	Over Active Bladder	1
4	Completed	Not Available	Over Active Bladder / Urinary Incontinence (UI)	1
4	Completed	Treatment	Adenocarcinoma, Prostate	1
4	Completed	Treatment	Over Active Bladder	4
4	Completed	Treatment	Over Active Bladder / Urge Urinary Incontinence	1
4	Completed	Treatment	Urinary Bladder, Overactive	4
4	Recruiting	Treatment	Over Active Bladder	1
4	Recruiting	Treatment	Parkinson's Disease (PD) / Urinary Bladder, Overactive	1
4	Terminated	Treatment	Over Active Bladder	1
4	Unknown Status	Treatment	Bladder Outlet Obstruction	1
Not Available	Active Not Recruiting	Not Available	Over Active Bladder / Urinary Bladder Diseases / Urinary Bladder Overactive / Urologic Diseases	1
Not Available	Completed	Not Available	Over Active Bladder	4
Not Available	Completed	Not Available	Overactive Bladder (OAB)	1
Not Available	Unknown Status	Not Available	Over Active Bladder	1
Not Available	Unknown Status	Treatment	Urinary Bladder, Overactive	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Tablet, extended release	Oral	4 mg
Tablet, extended release	Oral	8 mg
Tablet, film coated, extended release	Oral	4 mg/1
Tablet, film coated, extended release	Oral	8 mg/1

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6858650	No	2002-07-03	2022-07-03	US
US7384980	No	1999-05-11	2019-05-11	US
US7807715	No	2007-06-07	2027-06-07	US
US7855230	No	1999-05-11	2019-05-11	US
US7985772	No	1999-05-11	2019-05-11	US
US8088398	No	2007-06-07	2027-06-07	US
US8338478	No	1999-05-11	2019-05-11	US
US8501723	No	2007-06-07	2027-06-07	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Highly soluble	MSDS

Predicted Properties

Property	Value	Source
Water Solubility	0.00205 mg/mL	ALOGPS
logP	5.45	ALOGPS
logP	5.7	ChemAxon
logS	-5.3	ALOGPS
pKa (Strongest Acidic)	14.98	ChemAxon
pKa (Strongest Basic)	10.64	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	49.77 Å²	ChemAxon
Rotatable Bond Count	11	ChemAxon
Refractivity	124.08 m³·mol^-1	ChemAxon
Polarizability	48.29 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9535
Blood Brain Barrier	+	0.5648
Caco-2 permeable	+	0.7699
P-glycoprotein substrate	Substrate	0.5268
P-glycoprotein inhibitor I	Non-inhibitor	0.5556
P-glycoprotein inhibitor II	Non-inhibitor	0.625
Renal organic cation transporter	Inhibitor	0.6025
CYP450 2C9 substrate	Non-substrate	0.6853
CYP450 2D6 substrate	Non-substrate	0.5151
CYP450 3A4 substrate	Substrate	0.5939
CYP450 1A2 substrate	Inhibitor	0.6306
CYP450 2C9 inhibitor	Non-inhibitor	0.7227
CYP450 2D6 inhibitor	Inhibitor	0.6255
CYP450 2C19 inhibitor	Non-inhibitor	0.7334
CYP450 3A4 inhibitor	Non-inhibitor	0.5718
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6144
Ames test	Non AMES toxic	0.646
Carcinogenicity	Non-carcinogens	0.7213
Biodegradation	Not ready biodegradable	0.9385
Rat acute toxicity	2.4003 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9196
hERG inhibition (predictor II)	Inhibitor	0.5602

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Benzenoids

Sub Class

Benzene and substituted derivatives

Direct Parent

Diphenylmethanes

Alternative Parents

Phenol esters / Phenoxy compounds / Benzyl alcohols / Aralkylamines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Primary alcohols / Organopnictogen compounds

Substituents

Diphenylmethane / Phenol ester / Phenoxy compound / Benzyl alcohol / Aralkylamine / Amino acid or derivatives / Carboxylic acid ester / Tertiary amine / Tertiary aliphatic amine / Carboxylic acid derivative

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

Not Available

Targets

Details

1. Muscarinic acetylcholine receptor M3

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Receptor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM3
Uniprot ID:: P20309
Uniprot Name:: Muscarinic acetylcholine receptor M3
Molecular Weight:: 66127.445 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]

Details

2. Muscarinic acetylcholine receptor M4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Guanyl-nucleotide exchange factor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:: CHRM4
Uniprot ID:: P08173
Uniprot Name:: Muscarinic acetylcholine receptor M4
Molecular Weight:: 53048.65 Da

References

Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Details

3. Muscarinic acetylcholine receptor M1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Phosphatidylinositol phospholipase c activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM1
Uniprot ID:: P11229
Uniprot Name:: Muscarinic acetylcholine receptor M1
Molecular Weight:: 51420.375 Da

References

Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7. [PubMed:12076307 ]

Details

4. Muscarinic acetylcholine receptor M2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: G-protein coupled acetylcholine receptor activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:: CHRM2
Uniprot ID:: P08172
Uniprot Name:: Muscarinic acetylcholine receptor M2
Molecular Weight:: 51714.605 Da

References

Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Details

5. Muscarinic acetylcholine receptor M5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Phosphatidylinositol phospholipase c activity
Specific Function:: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:: CHRM5
Uniprot ID:: P08912
Uniprot Name:: Muscarinic acetylcholine receptor M5
Molecular Weight:: 60073.205 Da

References

Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. doi: 10.1124/jpet.108.145508. Epub 2008 Nov 24. [PubMed:19029429 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]

Details

2. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Uniprot Name:: Cytochrome P450 2D6
Molecular Weight:: 55768.94 Da

References

Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. [PubMed:19000553 ]
Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. [PubMed:21545485 ]
Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. doi: 10.1007/s00228-009-0648-1. Epub 2009 Apr 4. [PubMed:19347334 ]
Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8. [PubMed:19761716 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Chancellor MB, Staskin DR, Kay GG, Sandage BW, Oefelein MG, Tsao JW: Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. doi: 10.2165/11597530-000000000-00000. [PubMed:22390261 ]

Drug created on May 06, 2010 10:47 / Updated on July 25, 2017 17:56

Get DrugBank to go!

Structure for DB06702 (Fesoterodine)

Targets

References

References

References

References

References

Enzymes

References

References

Transporters

References